Skip to main content

Advertisement

Fig. 1 | BMC Pulmonary Medicine

Fig. 1

From: Reliever salbutamol use as a measure of exacerbation risk in chronic obstructive pulmonary disease

Fig. 1

Short-term (days 0–21) exacerbation risk. Kaplan-Meier plot of patients with occurrence of an exacerbation after they used for the first time >4, >10, or >20 inhalations of salbutamol per day in a) FORM and b) BUD/FORM treatment groups. Data for 16 patients are missing from baseline to day 0. BUD budesonide, COPD chronic obstructive pulmonary disease, FORM formoterol

Back to article page